# Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report

## TL;DR

A 6-year-old girl with cystic fibrosis developed rosacea symptoms after starting a new treatment, suggesting a possible drug-induced reaction.

## Contribution

This is the first reported case linking elexacaftor-tezacaftor-ivacaftor treatment to rosacea symptoms.

## Key findings

- Rosacea symptoms occurred after initiating elexacaftor-tezacaftor-ivacaftor therapy.
- Symptoms improved when the drug was discontinued and recurred upon reintroduction.
- The association may involve microbiome changes and inflammation.

## Abstract

A 6-year-old girl with cystic fibrosis developed ocular and cutaneous rosacea after the initiation of elexacaftor-tezacaftor-ivacaftor therapy. Her symptoms improved upon discontinuation and recurred with reintroduction, suggesting a drug-induced reaction. This case suggests a potential, previously unreported association between elexacaftor-tezacaftor-ivacaftor and rosacea, possibly mediated by microbiome alterations and inflammation.